Even though the net position and cash burn will reduce this quarter and more importantly in FY17, one needs to take into account that the savings will be partly offset by expenditure on the Phase III HF trial that was previously funded by Teva.
This isn't a hidden fact. Its MSB resuming control of the HF trial and its own destiny.
Thats the bigger picture!
Appendix 4C
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.255B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.07 | $6.931M | 6.287M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 42006 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 186215 | 33 |
View Market Depth
| Last trade - 15.26pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |